CJC-1295 vs MK-677: Oral vs Injectable for Growth Hormone
Here is how these two compounds compare — based on published research, not marketing claims.
CJC-1295
27
Indexed Studies
Animal Studies
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
MK-677 (Ibutamoren)
134
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
Both CJC-1295 and MK-677 increase growth hormone levels. The practical difference: MK-677 is a pill you swallow. CJC-1295 is an injection. That distinction matters for adherence, side effects, and the research behind each one. MK-677 has more human studies. CJC-1295 has a cleaner side effect profile. This comparison breaks down when each approach makes more sense.
Key Differences
| Attribute | CJC-1295 | MK-677 (Ibutamoren) |
|---|---|---|
| Evidence Level | Animal Studies | Human Trials |
| Category | GHRH Analog | Growth Hormone Secretagogue |
| Human Data | A few human pharmacokinetic studies demonstrating sustained GH and IGF-1 elevation. Less extensive than MK-677. | Substantial. Multiple human studies including a 2-year trial in elderly subjects (Murphy et al.). Data covers GH elevation, body composition, bone density, and sleep. More human evidence than CJC-1295. |
| Safety Profile | Limited but generally favorable safety data. Common side effects include injection site reactions, water retention, and numbness or tingling. No serious safety signals in published studies. | More side effects than CJC-1295. Increased appetite is common and can be significant. May elevate blood glucose and insulin levels. Water retention and lethargy reported. Long-term metabolic effects need monitoring. |
| Key Limitations | Requires injection. Fewer completed human trials than MK-677. The DAC version creates sustained (not pulsatile) GH elevation, which some researchers consider less physiological. | Appetite increase can be problematic. Glucose and insulin effects require monitoring. The metabolic trade-offs may limit long-term use for some individuals. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
CJC-1295
A modified version of growth hormone-releasing hormone that binds to GHRH receptors on the pituitary. The DAC (Drug Affinity Complex) version extends its half-life to several days, producing sustained GH elevation rather than a single pulse.
MK-677 (Ibutamoren)
An oral ghrelin mimetic that activates the ghrelin receptor to stimulate GH release. Also increases appetite through the same ghrelin pathway. Think of it as flipping the hunger-and-growth switch simultaneously.
CJC-1295 works through the GHRH pathway — the same system your hypothalamus uses to tell the pituitary to make GH. MK-677 works through the ghrelin pathway — the same system your stomach uses to signal hunger and trigger GH release. Both raise GH, but MK-677 also strongly stimulates appetite because ghrelin is the hunger hormone. CJC-1295 does not significantly affect appetite.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 161 indexed studies. Here are the key findings.
MK-677 is at L3 with multiple completed human trials including long-term data. CJC-1295 is at L2 with fewer but supportive human pharmacokinetic studies. MK-677 has the stronger evidence base for human outcomes. CJC-1295 has less published data but fewer metabolic side effects.
If avoiding injections is a priority, MK-677 is the only oral option with meaningful human data.
If appetite increase is a concern, CJC-1295 does not significantly stimulate appetite.
If metabolic health markers need to stay clean (glucose, insulin), CJC-1295 has a more favorable profile.
If the priority is the strongest available human evidence for GH elevation, MK-677 has more published data.
Key Limitations
- •No head-to-head trial comparing CJC-1295 and MK-677.
- •MK-677's metabolic effects (glucose, insulin) may limit its suitability for some users.
- •CJC-1295 DAC creates sustained GH elevation that may not be ideal for all applications.
- •Long-term outcome data comparing oral vs injectable GH optimization does not exist.
PSI Verdict
SUPPORTED BY EVIDENCE
Both CJC-1295 and MK-677 effectively elevate growth hormone and IGF-1 levels in humans. MK-677 has more extensive human trial data including a 2-year study. CJC-1295 produces sustained GH elevation with fewer metabolic side effects than MK-677.
NOT YET ESTABLISHED
Long-term clinical outcomes (muscle gain, fat loss, aging markers) from either compound have not been established in large controlled trials. Whether sustained GH elevation from either approach translates to meaningful health benefits remains unproven.
CONFIDENCE LEVEL
MK-677 has the better evidence base. CJC-1295 has the better side effect profile. If you need human data to support a decision, MK-677 provides more. If metabolic cleanliness matters, CJC-1295 is the safer bet.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
CJC-1295
"CJC-1295 with DAC gives you sustained growth hormone elevation for days"Supported by published data
"Stacking CJC-1295 with ipamorelin is the gold standard for GH optimization"Plausible but unproven
"It made me retain water and feel bloated"Supported by published data
MK-677 (Ibutamoren)
"MK-677 increased my growth hormone levels significantly"Supported by published data
"It made me hungry all the time and I gained fat"Supported by published data
"I use it for better sleep and recovery"Plausible but unproven
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
CJC-1295
Limited but generally favorable safety data. Common side effects include injection site reactions, water retention, and numbness or tingling. No serious safety signals in published studies.
MK-677 (Ibutamoren)
More side effects than CJC-1295. Increased appetite is common and can be significant. May elevate blood glucose and insulin levels. Water retention and lethargy reported. Long-term metabolic effects need monitoring.
MK-677 has more reported side effects: increased appetite, water retention, elevated blood glucose, and insulin resistance with long-term use. CJC-1295 has fewer metabolic side effects but requires injection and has less long-term safety data. Both need medical supervision.
WHAT THE RESEARCH SUGGESTS
MK-677 is the easier option to take and has more published human data. CJC-1295 is cleaner metabolically but requires injection. The choice often comes down to whether the convenience of oral dosing outweighs the metabolic trade-offs.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.